Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Tischkowitz

Showing results (211-220 of 258) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2022
Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic VariantsShuai Li, Valentina Silvestri, Goska Leslie, et al.
Breast Cancer Research : BCR|November 13, 2016
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 womenTimothy R Rebbeck, Tara M Friebel, Nandita Mitra, et al.
European Urology|February 4, 2014
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyElizabeth K Bancroft, Elizabeth C Page, Elena Castro, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.
European Urology|February 19, 2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT StudyElizabeth K Bancroft, Elizabeth C Page, Jana McHugh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 FamiliesXin Yang, Goska Leslie, Alicja Doroszuk, et al.
European Urology|September 21, 2019
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation CarriersElizabeth C Page, Elizabeth K Bancroft, Mark N Brook, et al.
Plos Genetics|April 2, 2013
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer riskMia M Gaudet, Karoline B Kuchenbaecker, Joseph Vijai, et al.
Journal of the National Cancer Institute|October 13, 2018
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization StudyFrank Qian, Shengfeng Wang, Jonathan Mitchell, et al.
Pageof 26

Showing results (211-220 of 258) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2022
Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic VariantsShuai Li, Valentina Silvestri, Goska Leslie, et al.
Breast Cancer Research : BCR|November 13, 2016
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 womenTimothy R Rebbeck, Tara M Friebel, Nandita Mitra, et al.
European Urology|February 4, 2014
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyElizabeth K Bancroft, Elizabeth C Page, Elena Castro, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.
European Urology|February 19, 2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT StudyElizabeth K Bancroft, Elizabeth C Page, Jana McHugh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 FamiliesXin Yang, Goska Leslie, Alicja Doroszuk, et al.
European Urology|September 21, 2019
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation CarriersElizabeth C Page, Elizabeth K Bancroft, Mark N Brook, et al.
Plos Genetics|April 2, 2013
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer riskMia M Gaudet, Karoline B Kuchenbaecker, Joseph Vijai, et al.
Journal of the National Cancer Institute|October 13, 2018
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization StudyFrank Qian, Shengfeng Wang, Jonathan Mitchell, et al.
Pageof 26